Literature DB >> 16328383

Characterization of the gammadelta T cell response to acute leukemia.

Paul F Meeh1, Michelle King, Rebecca L O'Brien, Stephanie Muga, Philip Buckhalts, Ronnie Neuberg, Lawrence S Lamb.   

Abstract

BACKGROUND: Previous work from our center has suggested a correlation between increased donor-derived Vdelta1+ gammadelta T cells and long-term relapse-free survival following bone marrow transplantation for leukemia. Questions remain, however, as to whether this observation can be explained by a gammadelta T cell-based immune response against primary leukemia.
METHODS: We examined gammadelta T cell receptor (TCR) phenotype, cell proliferation, and cytolytic activity following culture with irradiated primary leukemia blasts from a haploidentical first-degree relative. Subsequently, we also studied the gammadelta TCR phenotype and complimentarity determining region 3 (CDR3) cDNA sequences from 17 newly diagnosed leukemia patients.
RESULTS: In 17/28 (61%) of in vitro cultures, gammadelta T cells proliferated in culture with primary blasts. Vdelta1+ T cells were proportionally increased in all cultures and were the predominant cell population in 6/17. In the 7 cultures where cytotoxicity could be assessed, 6 (86%) showed some degree of cytotoxicity to the primary leukemia. Vdelta1+ T cells were also the predominant gammadelta T cell subtype in pre-treatment leukemia patients principally due to loss of Vdelta2+ T cells rather than expansion of Vdelta1+ cells. The Vdelta1 CDR3-region cDNA sequence from these patients revealed exclusive use of the Jdelta1 constant region and sequence conservation in 4/11 patients.
CONCLUSIONS: gammadelta T cells exhibit an in vitro response to primary leukemia blasts that is manifested by proliferation, an increased proportion of Vdelta1+ T cells, and cytotoxicity to the primary leukemia blasts. The Vdelta1+ T cell population is also predominant in newly diagnosed leukemia patients likely due to a loss of circulating Vdelta2+ T cells. A small proportion of newly diagnosed patients showed Vdelta1 CDR3 region similarity. These findings suggest a role for gammadelta T cells in the immune response to leukemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16328383     DOI: 10.1007/s00262-005-0094-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  26 in total

Review 1.  Gammadelta T cells as immune effectors against high-grade gliomas.

Authors:  Lawrence S Lamb
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

2.  In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment.

Authors:  Guranda Chitadze; Charlotte Flüh; Elgar Susanne Quabius; Sandra Freitag-Wolf; Christian Peters; Marcus Lettau; Jaydeep Bhat; Daniela Wesch; Hans-Heinrich Oberg; Stefanie Luecke; Ottmar Janssen; Michael Synowitz; Janka Held-Feindt; Dieter Kabelitz
Journal:  Oncoimmunology       Date:  2017-08-08       Impact factor: 8.110

3.  BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia.

Authors:  Audrey Benyamine; Aude Le Roy; Emilie Mamessier; Julie Gertner-Dardenne; Céline Castanier; Florence Orlanducci; Laurent Pouyet; Armelle Goubard; Yves Collette; Norbert Vey; Emmanuel Scotet; Remy Castellano; Daniel Olive
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

Review 4.  Contemporary haploidentical stem cell transplant strategies in children with hematological malignancies.

Authors:  Ravi M Shah
Journal:  Bone Marrow Transplant       Date:  2021-03-05       Impact factor: 5.483

5.  Targeting γδ T cells for immunotherapy of HIV disease.

Authors:  C David Pauza; David J Riedel; Bruce L Gilliam; Robert R Redfield
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

6.  Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer.

Authors:  Chunling Ma; Qunyuan Zhang; Jian Ye; Fang Wang; Yanping Zhang; Eric Wevers; Theresa Schwartz; Pamela Hunborg; Mark A Varvares; Daniel F Hoft; Eddy C Hsueh; Guangyong Peng
Journal:  J Immunol       Date:  2012-10-03       Impact factor: 5.422

Review 7.  Depletion and dysfunction of Vγ2Vδ2 T cells in HIV disease: mechanisms, impacts and therapeutic implications.

Authors:  Haishan Li; Suchita Chaudhry; Suchita Chaudry; Bhawna Poonia; Yiming Shao; C David Pauza
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

8.  Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.

Authors:  Nichole L Bryant; Catalina Suarez-Cuervo; G Yancey Gillespie; James M Markert; L Burt Nabors; Sreelatha Meleth; Richard D Lopez; Lawrence S Lamb
Journal:  Neuro Oncol       Date:  2009-02-11       Impact factor: 12.300

Review 9.  Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field?

Authors:  Gabrielle M Siegers; Lawrence S Lamb
Journal:  Mol Ther       Date:  2014-06-04       Impact factor: 11.454

10.  Analysis of Immune Cells from Human Mammary Ductal Epithelial Organoids Reveals Vδ2+ T Cells That Efficiently Target Breast Carcinoma Cells in the Presence of Bisphosphonate.

Authors:  Nicholas A Zumwalde; Jill D Haag; Deepak Sharma; Jennifer A Mirrielees; Lee G Wilke; Michael N Gould; Jenny E Gumperz
Journal:  Cancer Prev Res (Phila)       Date:  2016-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.